| Literature DB >> 32520951 |
Ravindra Daddali1,2, Marja Ojaniemi1,2, Mikko Hallman1,2, Mika Rämet1,2,3, Antti M Haapalainen1,2.
Abstract
MicroRNAs (miRNAs) are important regulators of gene expression, and their expression is associated with many physiological conditions. Here, we investigated potential associations between expression levels of miRNAs in human placenta and the onset of spontaneous term birth. Using RNA sequencing, we identified 54 miRNAs differentially expressed during spontaneous term labor compared to elective term births. Expression levels of 23 miRNAs were upregulated, whereas 31 were downregulated at least 1.5-fold. The upregulated miRNA miR-371a-5p putatively targets CPPED1, expression of which decreases during spontaneous birth. We used a luciferase reporter-based assay to test whether a miR-371a-5p mimic affected translation when it bound to the 3' untranslated region of CPPED1. In this setting, the miR-371a-5p mimic resulted in lower luciferase activity, which suggests that miR-371a-5p regulates levels of CPPED1. In conclusion, inversely correlated levels of miR-371a-5p and CPPED1 suggest a role for both in spontaneous delivery.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32520951 PMCID: PMC7286509 DOI: 10.1371/journal.pone.0234403
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CPPED1 mRNA levels in preterm and term placentas.
Normalized expression levels of CPPED1 in human preterm and term placentas to compare spontaneous and elective deliveries. CPPED1 expression was decreased during spontaneous preterm birth in the chorionic plate (right panel) but not in the basal plate (left panel). At spontaneous term birth, CPPED1 mRNA levels decreased in both basal and chorionic plates. There was no difference in CPPED1 expression in placentas from preterm and term spontaneous and elective deliveries. Differences were analyzed with nonparametric Kruskall–Wallis test. Horizontal line denotes the median of each group. Statistically significant changes are indicated by one (p < 0.05) and three (p < 0.001) asterisks; NS, not significant. Preeclampsia and intra-amniotic inflammation cases are indicated by an open circle.
Up- and downregulated human placenta miRNAs at spontaneous term labor.
MiRNAs isolated from human placenta after spontaneous term labor were compared with miRNAs of placentas obtained from elective deliveries by caesarean section without signs or symptoms of labor. Thresholds used in filtering differentially expressed miRNAs were fold-change (FC) more or less than 1.5 and p value < 0.05. MiRNAs were ranked based on both t-test p value and FC. In the average rank column, the value 1 is the strongest differentially expressed miRNA. Up- and downregulated miRNAs are shown in red and green, respectively. Chromosomal locations of miRNAs belonging to either C14MC or miR-371-3 cluster are highlighted in orange.
| MicroRNA | Average rank | Fold-change | Chromosomal location | |
|---|---|---|---|---|
| hsa-miR-373-3p | 2 | 2.61 | 0.001 | 19q13.42 |
| hsa-miR-371a-5p | 6 | 2.47 | 0.003 | 19q13.42 |
| hsa-miR-371b-3p | 7 | 2.34 | 0.003 | 19q13.42 |
| hsa-miR-372-3p | 11 | 2.16 | 0.007 | 19q13.42 |
| hsa-miR-323b-3p | 15 | 1.83 | 0.008 | 14q32.31 |
| hsa-miR-760 | 23 | 1.70 | 0.007 | 1p22.1 |
| hsa-miR-1254 | 26 | 1.63 | 0.007 | NA |
| hsa-miR-551a | 28 | 1.67 | 0.009 | 1p36.32 |
| hsa-miR-184 | 29 | 1.66 | 0.012 | 15q25.1 |
| hsa-miR-6511b-3p | 30 | 1.70 | 0.017 | 16p13.3 |
| hsa-miR-4707-5p | 38 | 1.60 | 0.022 | 14q11.2 |
| hsa-miR-372-5p | 39 | 1.62 | 0.026 | 19q13.42 |
| hsa-miR-509-3p | 40 | 1.62 | 0.025 | Xq27.3 |
| hsa-miR-6779-5p | 44 | 1.54 | 0.018 | 17q12 |
| hsa-miR-504-5p | 46 | 1.68 | 0.040 | Xq26.3 |
| hsa-miR-99b-3p | 48 | 1.49 | 0.014 | 19q13.41 |
| hsa-miR-3140-3p | 50 | 1.49 | 0.016 | 4q31.3 |
| hsa-miR-133a-3p | 52 | 1.52 | 0.021 | 18q11.2 |
| hsa-miR-205-5p | 54 | 1.60 | 0.036 | 1q32.2 |
| hsa-miR-877-5p | 59 | 1.49 | 0.023 | 6p21.33 |
| hsa-miR-551b-5p | 67 | 1.53 | 0.044 | 3q26.2 |
| hsa-miR-449c-3p | 71 | 1.46 | 0.033 | 5q11.2 |
| hsa-miR-4665-3p | 73 | 1.47 | 0.038 | 9p24.1 |
| hsa-miR-4732-5p | 1 | -3.28 | 0.001 | 17q11.2 |
| hsa-miR-6743-5p | 4 | -2.50 | 0.001 | 11p15.5 |
| hsa-miR-1272 | 5 | -2.86 | 0.005 | 15q22.31 |
| hsa-miR-6765-3p | 8 | -2.35 | 0.004 | 14q32.33 |
| hsa-miR-6872-3p | 9 | -2.08 | 0.004 | 3p21.31 |
| hsa-miR-135a-5p | 13 | -4.79 | 0.026 | 3p21.2 |
| hsa-miR-3144-3p | 14 | -1.97 | 0.009 | 6q22.31 |
| hsa-miR-5100 | 16 | -1.86 | 0.010 | 10q11.21 |
| hsa-miR-6865-5p | 17 | -1.79 | 0.007 | 17p13.2 |
| hsa-miR-501-5p | 18 | -1.99 | 0.013 | Xp11.23 |
| hsa-miR-5196-5p | 19 | -1.82 | 0.010 | 19q13.12 |
| hsa-miR-2277-3p | 20 | -2.06 | 0.016 | 5q15 |
| hsa-miR-1260a | 21 | -1.68 | 0.002 | 14q24.3 |
| hsa-miR-1909-3p | 22 | -1.84 | 0.014 | 19p13.3 |
| hsa-miR-4286 | 24 | -1.70 | 0.011 | 8p23.1 |
| hsa-let-7g-3p | 27 | -1.80 | 0.020 | 3p21.2 |
| hsa-miR-1292-5p | 34 | -1.68 | 0.027 | 20p13 |
| hsa-miR-4784 | 35 | -1.63 | 0.026 | 2q21.1 |
| hsa-miR-4304 | 37 | -1.53 | 0.013 | 12q24.31 |
| hsa-miR-3928-5p | 41 | -1.70 | 0.038 | 22q12.2 |
| hsa-miR-4664-5p | 42 | -1.53 | 0.014 | 8q24.3 |
| hsa-miR-451a | 45 | -1.62 | 0.033 | 17q11.2 |
| hsa-miR-6069 | 47 | -1.46 | 0.008 | 22q12.3 |
| hsa-miR-3614-3p | 49 | -1.52 | 0.018 | 17q22 |
| hsa-miR-3117-3p | 53 | -1.54 | 0.026 | 1p31.3 |
| hsa-miR-7850-5p | 57 | -1.48 | 0.020 | 19p13.3 |
| hsa-miR-3922-5p | 58 | -1.55 | 0.036 | 12q23.3 |
| hsa-miR-1908-3p | 61 | -1.60 | 0.044 | 11q12.2 |
| hsa-miR-6763-5p | 62 | -1.58 | 0.042 | 12q24.33 |
| hsa-miR-6071 | 63 | -1.50 | 0.027 | 2p11.2 |
| hsa-miR-7977 | 64 | -1.46 | 0.022 | 3q26.32 |
Human placental miRNAs and their experimentally validated targets.
MiRNAs that were either up- (red) or down- (green) regulated at the onset of labor and have validated targets are shown. Listed miRNA targets were obtained with miRTarBase software. All miRNA–target interactions have been validated by reporter assay, western blot, and/or qPCR. miRNAs are in the same order as listed in Table 1.
| MicroRNA | Validated targets |
|---|---|
| hsa-miR-373-3p | BTG1, CD44, CSDC2, DKK1, IRF9, JAK1, LATS2, LEFTY1, LEFTY2, MBD2, MRE11, MTOR, MYC, NFIB, PIK3CA, RABEP1, RAD23B, RAD52, RASSF1, RECK, SIRT1, TGFBR2, TNFAIP1, TXNIP, VEGFA, XPA |
| hsa-miR-371a-5p | CDH1, HSP90AA1, PRPF4B, PTENP1, SOX2 |
| hsa-miR-372-3p | ATAD2, BTG1, CCNA1, CDK2, CDKN1A, DKK1, ERBB4, KLF13, LATS2, LEFTY1, MBNL2, NFIB, NR4A2, PHLPP2, RHOC, TGFBR2, TNFAIP1, TRPS1, TXNIP, WEE1, VEGFA |
| hsa-miR-760 | CSNK2A1, HIST1H2AD, HIST1H3D |
| hsa-miR-1254 | CCAR1 |
| hsa-miR-551a | CKB, PTP4A3 |
| hsa-miR-184 | AGO2, AKT1, AKT2, BCL2, BIN3, EZR, GAS1, INPPL1, MYC, NFATC2, PDGFB, PKM, PLPP3, PPP1R13L, PRKCB, SND1, SOX7, TNFAIP2, ZFPM2 |
| hsa-miR-509-3p | CFTR, MAP3K8, NTRK3, XIAP, YAP1 |
| hsa-miR-504-5p | BAX, BBC3, CDK6, DRD1, FAS, GADD45A, MDM2, TCEAL1, TFF1, TP53, TP53I3, VEGFA |
| hsa-miR-99b-3p | GSK3B |
| hsa-miR-133a-3p | CDC42, HCN4, UCP2, KRT7, CACNA1C, HCN2, CASP9, KCNQ1, FSCN1, KCNH2, TAGLN2, LASP1, PNP, MSN, EGFR, VKORC1, PRDM16, ARPC5, FTL, EGFL7, VEGFA, PIK3R2, RGS3, COL1A1, SP1, BCL2L1, MCL1, RFFL, IGF1R, UBA2, ANXA2, MMP14, SNX30, SGMS2, PDLIM5, IGF1, ZEB1, CTGF, LDLRAP1, NR2C2, MEG3, AFTPH, ERBB2, FOXl2, SOX4, RBPJ, NGFR, GSTP1 |
| hsa-miR-205-5p | LRP1, ZEB1, DDX5, INPPL1, MED1, E2F5, E2F1, ERBB3, ZEB2, PRKCE, VEGFA, SIGMAR1, IL24, IL32, EGLN2, TP73, CYR61, CTGF, ERBB2, LAMC1, LRRK2, YES1, SRC, BCL2, SMAD1, SMAD4, YY1, PTPRM, AR, BCL6, ACSL4, ITGA5, ACSL1, HMGB3, PTEN, ESRRG, PHLPP2, KCNJ10, EZR, LMNA, RUNX2, HMGB1, PRDX2, SMAD2, UVRAG, CENPF, SATB2, CCNJ |
| hsa-miR-135a-5p | JAK2, NR3C2, APC, HOXA10, MYC, SMAD5, BMPR2, STAT6, MTSS1, ROCK1, VLDLR, TXNIP, IRS2, APC, HTR1A, SLC6A4, SIAH1, BCL2, KLF8, ESRRA, RUNX2, ROCK2, FOXO1, PHLPP2, E2F1, DAPK2, KLF4, PTPRD, PTK2, CEBPD, PPM1E, MMP11, RBAK, EGFR |
| hsa-miR-501-5p | AKT2, DKK1, DNAJB14, INPPL1, LAMTOR5, NFATC2, NKD1 |
| hsa-let-7g-3p | CCL2, CCL5, MYBPC3 |
| hsa-miR-1292-5p | SOX4 |
| hsa-miR-4304 | AKT2, INPPL1, NFATC2 |
| hsa-miR-451a | ABCB1, ADAM10, AKT1, BCL2, CAB39, CDKN2D, CPNE3, DCBLD2, FRZB, IKBKB, IL6, IL6R, MAP3K1, MAPK1, MIF, MMP2, MMP9, MYC, OSR1, OXTR, PKD1, RAB14, RAB5A, ROR2, TMED7, TSC1 |
Functional annotation of miRNA targets associated with spontaneous term birth.
Clustering was performed by DAVID analysis [43] according to KEGG pathways and used all of the identified miRNA targets listed in Table 2. KEGG terms with false discovery rate (FDR)–adjusted p values of <0.05 are shown. In functional annotation clustering, KEGG terms highlighted in orange comprised the most significant cluster, with an enrichment score of 16.05.
| KEGG term | Number of genes involved in the KEGG term | Benjamini-Hochberg–corrected | FDR-adjusted | |
|---|---|---|---|---|
| hsa05200:Pathways in cancer | 50 | 6.30 × 10−24 | 1.27 × 10−21 | 7.90 × 10−21 |
| hsa05215:Prostate cancer | 24 | 1.07 × 10−18 | 1.08 × 10−16 | 1.34 × 10−15 |
| hsa05161:Hepatitis B | 28 | 1.05 × 10−17 | 7.05 × 10−16 | 1.32 × 10−14 |
| hsa05205:Proteoglycans in cancer | 31 | 7.33 × 10−17 | 5.55 × 10−15 | 1.44 × 10−13 |
| hsa05212:Pancreatic cancer | 19 | 2.61 × 10−15 | 1.03 × 10−13 | 3.21 × 10−12 |
| hsa05206:MicroRNAs in cancer | 33 | 3.87 × 10−14 | 1.29 × 10−12 | 4.85 × 10−11 |
| hsa04151:PI3K-Akt signaling pathway | 36 | 4.07 × 10−14 | 1.17 × 10−12 | 5.10 × 10−11 |
| hsa05219:Bladder cancer | 15 | 1.44 × 10−13 | 3.61 × 10−12 | 1.80 × 10−10 |
| hsa04068:FoxO signaling pathway | 23 | 2.33 × 10−13 | 5.21 × 10−12 | 2.93 × 10−10 |
| hsa05214:Glioma | 17 | 7.59 × 10−13 | 1.52 × 10−11 | 9.52 × 10−10 |
| hsa05218:Melanoma | 16 | 4.43 × 10−11 | 8.09 × 10−10 | 5.55 × 10−08 |
| hsa05222:Small cell lung cancer | 17 | 6.19 × 10−11 | 1.04 × 10−09 | 7.76 × 10−08 |
| hsa05210:Colorectal cancer | 15 | 7.80 × 10−11 | 1.21 × 10−09 | 9.79 × 10−08 |
| hsa05213:Endometrial cancer | 14 | 9.58 × 10−11 | 1.37 × 10−09 | 1.20 × 10−07 |
| hsa04510:Focal adhesion | 24 | 2.35 × 10−10 | 3.15 × 10−09 | 2.95 × 10−07 |
| hsa04115:p53 signaling pathway | 15 | 2.38 × 10−10 | 2.98 × 10−09 | 2.98 × 10−07 |
| hsa04066:HIF-1 signaling pathway | 17 | 4.19 × 10−10 | 4.95 × 10−09 | 5.25 × 10−07 |
| hsa05220:Chronic myeloid leukemia | 15 | 6.57 × 10−10 | 7.33 × 10−09 | 8.24 × 10−07 |
| hsa04012:ErbB signaling pathway | 16 | 9.26 × 10−10 | 9.80 × 10−09 | 1.16 × 10−06 |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 19 | 2.55 × 10−09 | 2.56 × 10−08 | 3.20 × 10−06 |
| hsa05223:Non-small cell lung cancer | 13 | 3.56 × 10−09 | 3.41 × 10−08 | 4.46 × 10−06 |
| hsa05202:Transcriptional misregulation in cancer | 20 | 7.18 × 10−09 | 6.56 × 10−08 | 9.01 × 10−06 |
| hsa05230:Central carbon metabolism in cancer | 13 | 1.78 × 10−08 | 1.56 × 10−07 | 2.24 × 10−05 |
| hsa05162:Measles | 17 | 5.41 × 10−08 | 4.53 × 10−07 | 6.79 × 10−05 |
| hsa04520:Adherens junction | 13 | 6.05 × 10−08 | 4.86 × 10−07 | 7.59 × 10−05 |
| hsa04150:mTOR signaling pathway | 12 | 6.35 × 10−08 | 4.91 × 10−07 | 7.96 × 10−05 |
| hsa04370:VEGF signaling pathway | 12 | 1.10 × 10−07 | 8.17 × 10−07 | 1.38 × 10−04 |
| hsa04210:Apoptosis | 12 | 1.31 × 10−07 | 9.39 × 10−07 | 1.64 × 10−04 |
| hsa05166:HTLV-I infection | 22 | 3.12 × 10−07 | 2.16 × 10−06 | 3.92 × 10−04 |
| hsa04919:Thyroid hormone signaling pathway | 15 | 3.31 × 10−07 | 2.22 × 10−06 | 4.16 × 10−04 |
| hsa04350:TGF-beta signaling pathway | 13 | 4.12 × 10−07 | 2.67 × 10−06 | 5.17 × 10−04 |
| hsa04722:Neurotrophin signaling pathway | 15 | 5.64 × 10−07 | 3.54 × 10−06 | 7.08 × 10−04 |
| hsa05169:Epstein-Barr virus infection | 15 | 6.92 × 10−07 | 4.22 × 10−06 | 8.68 × 10−04 |
| hsa04152:AMPK signaling pathway | 15 | 7.66 × 10−07 | 4.53 × 10−06 | 9.61 × 10−04 |
| hsa04110:Cell cycle | 15 | 8.46 × 10−07 | 4.86 × 10−06 | 1.06 × 10−03 |
| hsa04390:Hippo signaling pathway | 16 | 1.77 × 10−06 | 9.87 × 10−06 | 2.22 × 10−03 |
| hsa04071:Sphingolipid signaling pathway | 14 | 3.40 × 10−06 | 1.85 × 10−05 | 4.26 × 10−03 |
| hsa04668:TNF signaling pathway | 13 | 5.71 × 10−06 | 3.02 × 10−05 | 7.16 × 10−03 |
| hsa05164:Influenza A | 16 | 1.03 × 10−05 | 5.32 × 10−05 | 1.30 × 10−03 |
| hsa04930:Type II diabetes mellitus | 9 | 1.17 × 10−05 | 5.90 × 10−05 | 1.47 × 10−02 |
| hsa05203:Viral carcinogenesis | 17 | 1.83 × 10−05 | 8.98 × 10−05 | 2.30 × 10−02 |
| hsa05231:Choline metabolism in cancer | 12 | 1.88 × 10−05 | 9.01 × 10−05 | 2.36 × 10−02 |
| hsa04666:Fc gamma R-mediated phagocytosis | 11 | 2.08 × 10−05 | 9.73 × 10−05 | 2.61 × 10−02 |
| hsa05142:Chagas disease (American trypanosomiasis) | 12 | 2.49 × 10−05 | 1.14 × 10−05 | 3.12 × 10−02 |
Functional annotation of miRNA targets of up- and downregulated miRNAs associated with spontaneous term birth.
Targets associated with either up- or downregulated miRNAs of Table 2 analyzed separately by DAVID analysis [43] according to KEGG pathways. Results for targets of up- and downregulated miRNAs are shown in red and green, respectively. KEGG terms with false discovery rate (FDR)–adjusted p values of < 0.05 are shown.
| KEGG Term | Number of genes involved in the KEGG term | Benjamini-Hochberg–corrected | FDR-adjusted | |
|---|---|---|---|---|
| hsa05200:Pathways in cancer | 39 | 4.61 × 10−19 | 8.99 × 10−17 | 5.75 × 10−16 |
| hsa05215:Prostate cancer | 21 | 1.75 × 10−17 | 1.71 × 10−15 | 2.18 × 10−14 |
| hsa05212:Pancreatic cancer | 17 | 9.64 × 10−15 | 6.28 × 10−13 | 1.21 × 10−11 |
| hsa05205:Proteoglycans in cancer | 25 | 3.92 × 10−14 | 1.91 × 10−12 | 4.89 × 10−11 |
| hsa05214:Glioma | 16 | 1.96 × 10−13 | 7.64 × 10−12 | 2.45 × 10−10 |
| hsa05161:Hepatitis B | 21 | 4.66 × 10−13 | 1.51 × 10−11 | 5.82 × 10−10 |
| hsa04151:PI3K-Akt signaling pathway | 29 | 4.48 × 10−12 | 1.25 × 10−10 | 5.59 × 10−09 |
| hsa05218:Melanoma | 15 | 1.31 × 10−11 | 3.20 × 10−10 | 1.64 × 10−08 |
| hsa05206:MicroRNAs in cancer | 26 | 1.52 × 10−11 | 3.29 × 10−10 | 1.89 × 10−08 |
| hsa04115:p53 signaling pathway | 14 | 9.16 × 10−11 | 1.79 × 10−09 | 1.14 × 10−07 |
| hsa05222:Small cell lung cancer | 15 | 1.69 × 10−10 | 2.99 × 10−09 | 2.10 × 10−07 |
| hsa05210:Colorectal cancer | 13 | 5.20 × 10−10 | 8.45 × 10−09 | 6.49 × 10−07 |
| hsa05213:Endometrial cancer | 12 | 1.04 × 10−09 | 1.56 × 10−08 | 1.29 × 10−06 |
| hsa04068:FoxO signaling pathway | 17 | 1.10 × 10−09 | 1.54 × 10−08 | 1.38 × 10−06 |
| hsa05219:Bladder cancer | 11 | 1.38 × 10−09 | 1.79 × 10−08 | 1.72 × 10−06 |
| hsa04510:Focal adhesion | 20 | 2.31 × 10−09 | 2.81 × 10−08 | 2.88 × 10−06 |
| hsa05223:Non-small cell lung cancer | 12 | 2.41 × 10−09 | 2.76 × 10−08 | 3.01 × 10−06 |
| hsa04012:ErbB signaling pathway | 14 | 2.75 × 10−09 | 2.98 × 10−08 | 3.43 × 10−06 |
| hsa05220:Chronic myeloid leukemia | 13 | 3.19 × 10−09 | 3.28 × 10−08 | 3.98 × 10−06 |
| hsa04066:HIF-1 signaling pathway | 14 | 9.50 × 10−09 | 9.26 × 10−08 | 1.19 × 10−05 |
| hsa05230:Central carbon metabolism in cancer | 12 | 1.07 × 10−08 | 9.92 × 10−08 | 1.33 × 10−05 |
| hsa04520:Adherens junction | 12 | 3.32 × 10−08 | 2.94 × 10−07 | 4.14 × 10−05 |
| hsa05162:Measles | 15 | 6.69 × 10−08 | 5.67 × 10−07 | 8.35 × 10−05 |
| hsa04210:Apoptosis | 11 | 9.70 × 10−08 | 7.88 × 10−07 | 1.21 × 10−04 |
| hsa05169:Epstein-Barr virus infection | 14 | 1.76 × 10−07 | 1.37 × 10−06 | 2.20 × 10−04 |
| hsa04110:Cell cycle | 14 | 2.13 × 10−07 | 1.60 × 10−06 | 2.66 × 10−04 |
| hsa04919:Thyroid hormone signaling pathway | 13 | 6.78 × 10−07 | 4.89 × 10−06 | 8.46 × 10−04 |
| hsa04370:VEGF signaling pathway | 10 | 9.61 × 10−07 | 6.69 × 10−06 | 1.20 × 10−03 |
| hsa05202:Transcriptional misregulation in cancer | 15 | 1.14 × 10−06 | 7.65 × 10−06 | 1.42 × 10−03 |
| hsa05166:HTLV-I infection | 18 | 1.82 × 10−06 | 1.18 × 10−05 | 2.27 × 10−03 |
| hsa04390:Hippo signaling pathway | 14 | 2.09 × 10−06 | 1.31 × 10−05 | 2.61 × 10−03 |
| hsa05203:Viral carcinogenesis | 16 | 2.59 × 10−06 | 1.58 × 10−05 | 3.23 × 10−03 |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 13 | 5.53 × 10−06 | 3.27 × 10−05 | 6.90 × 10−03 |
| hsa04722:Neurotrophin signaling pathway | 12 | 7.27 × 10−06 | 4.17 × 10−05 | 9.08 × 10−03 |
| hsa04666:Fc gamma R-mediated phagocytosis | 10 | 1.45 × 10−05 | 8.10 × 10−05 | 1.81 × 10−02 |
| hsa05161:Hepatitis B | 13 | 1.77 × 10−10 | 2.43 × 10−08 | 2.08 × 10−07 |
| hsa05200:Pathways in cancer | 17 | 3.97 × 10−09 | 2.72 × 10−07 | 4.67 × 10−06 |
| hsa05219:Bladder cancer | 7 | 3.13 × 10−07 | 1.43 × 10−05 | 3.68 × 10−04 |
| hsa05215:Prostate cancer | 8 | 2.12 × 10−06 | 7.26 × 10−05 | 2.49 × 10−03 |
| hsa04151:PI3K-Akt signaling pathway | 13 | 2.84 × 10−06 | 7.77 × 10−05 | 3.34 × 10−03 |
| hsa04068:FoxO signaling pathway | 9 | 3.29 × 10−06 | 7.52 × 10−05 | 3.87 × 10−03 |
| hsa04062:Chemokine signaling pathway | 10 | 4.30 × 10−06 | 8.41 × 10−05 | 5.05 × 10−03 |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 9 | 4.57 × 10−06 | 7.83 × 10−05 | 5.38 × 10−03 |
| hsa05205:Proteoglycans in cancer | 10 | 7.78 × 10−06 | 1.18 × 10−04 | 9.15 × 10−03 |
| hsa04668:TNF signaling pathway | 8 | 7.88 × 10−06 | 1.08 × 10−04 | 9.27 × 10−03 |
| hsa05206:MicroRNAs in cancer | 11 | 2.12 × 10−05 | 2.64 × 10−04 | 2.49 × 10−02 |
| hsa05222:Small cell lung cancer | 7 | 2.41 × 10−05 | 2.76 × 10−04 | 2.84 × 10−02 |
Number of predicted targets of miRNAs in the placental miRNAome.
Predicted targets for each miRNA were determined by analyzing an online database for miRNA target prediction and functional annotations (miRDB) [44,45]. The target prediction score was set between 50 and 100. Because of the high number of predicted targets for each miRNA, only the number of targets are shown. Results for targets of up- and downregulated miRNAs are shown in red and green, respectively. miRNAs are listed in the same order as in Table 1.
| MicroRNA | Number of predicted targets |
|---|---|
| hsa-miR-373-3p | 899 |
| hsa-miR-371a-5p | 876 |
| hsa-miR-371b-3p | 190 |
| hsa-miR-372-3p | 902 |
| hsa-miR-323b-3p | 323 |
| hsa-miR-760 | 690 |
| hsa-miR-1254 | NA |
| hsa-miR-551a | 21 |
| hsa-miR-184 | 70 |
| hsa-miR-6511b-3p | 341 |
| hsa-miR-4707-5p | 60 |
| hsa-miR-372-5p | 1050 |
| hsa-miR-509-3p | 282 |
| hsa-miR-6779-5p | 1225 |
| hsa-miR-504-5p | 317 |
| hsa-miR-99b-3p | 54 |
| hsa-miR-3140-3p | 1049 |
| hsa-miR-133a-3p | 654 |
| hsa-miR-205-5p | 737 |
| hsa-miR-877-5p | 354 |
| hsa-miR-551b-5p | 1632 |
| hsa-miR-449c-3p | 235 |
| hsa-miR-4665-3p | 7 |
| hsa-miR-4732-5p | 186 |
| hsa-miR-6743-5p | 339 |
| hsa-miR-1272 | 432 |
| hsa-miR-6765-3p | 536 |
| hsa-miR-6872-3p | 344 |
| hsa-miR-135a-5p | 804 |
| hsa-miR-3144-3p | 298 |
| hsa-miR-5100 | 502 |
| hsa-miR-6865-5p | 351 |
| hsa-miR-501-5p | 615 |
| hsa-miR-5196-5p | 1309 |
| hsa-miR-2277-3p | 154 |
| hsa-miR-1260a | 567 |
| hsa-miR-1909-3p | 800 |
| hsa-miR-4286 | 798 |
| hsa-let-7g-3p | 958 |
| hsa-miR-1292-5p | 132 |
| hsa-miR-4784 | 831 |
| hsa-miR-4304 | 53 |
| hsa-miR-3928-5p | 485 |
| hsa-miR-4664-5p | 469 |
| hsa-miR-451a | 40 |
| hsa-miR-6069 | 164 |
| hsa-miR-3614-3p | 315 |
| hsa-miR-3117-3p | 225 |
| hsa-miR-7850-5p | 549 |
| hsa-miR-3922-5p | 543 |
| hsa-miR-1908-3p | 11 |
| hsa-miR-6763-5p | 833 |
| hsa-miR-6071 | 819 |
| hsa-miR-7977 | 1276 |
Fig 2Mir-371a-5p levels in the basal plate of term placentas.
Normalized expression levels of miR-371a-5p in placentas from spontaneous and elective term births. In the miRNAomic study, miRNAs isolated from human placenta after spontaneous term labor (n = 6) were compared with miRNAs obtained from elective deliveries (n = 6) without signs of labor. Mir-371a-5p was the second most upregulated miRNA at spontaneous term labor (fold-change = 2.6, p = 0.003). This result was confirmed in a larger number of placental samples (n = 19 for spontaneous term labor, n = 14 for elective term labor). During spontaneous term labor, miR-371a5-p levels significantly increased by 1.5-fold (p = 0.04). Differences were analyzed with nonparametric Mann–Whitney U test. Horizontal line denotes the median of each group. NS, not significant.
Predicted miRNA binding sites in the 3′ UTR of CPPED1 mRNA.
Putative miRNA binding sites in the 3′ UTR of CPPED1 were analyzed with miRDB software [44,45]. Predicted targets with a prediction score of at least 80 were considered real. MiRNAs highlighted in orange belong to the placental chromosome 19 miRNA cluster (C19MC) or miR-371-3 cluster. In this study, miRNAs belonging to these clusters were checked for binding to the 3′ UTR of CPPED1 mRNA.
| Target rank | Target score | miRNA Name | Number of binding sites | Chromosomal location |
|---|---|---|---|---|
| 1 | 100 | hsa-miR-6867-5p | 4 | 17q21.1 |
| 2 | 96 | hsa-miR-4671-3p | 2 | 1q42.2 |
| 3 | 95 | hsa-miR-6801-5p | 2 | 19q13.41 |
| 4 | 95 | hsa-miR-10393-3p | 2 | 15q21.1 |
| 5 | 94 | hsa-miR-29b-2-5p | 4 | 1q32.2 |
| 6 | 94 | hsa-miR-1297 | 3 | 13q14.3 |
| 7 | 93 | hsa-miR-568 | 3 | 3q13.31 |
| 8 | 93 | hsa-miR-627-3p | 5 | 15q15.1 |
| 9 | 90 | hsa-miR-5696 | 3 | 2q11.2 |
| 10 | 88 | hsa-miR-26a-5p | 3 | 3p22.2 |
| 11 | 88 | hsa-miR-524-5p | 1 | 19q13.42 |
| 12 | 88 | hsa-miR-26b-5p | 3 | 2q35 |
| 13 | 88 | hsa-miR-520d-5p | 1 | 19q13.42 |
| 14 | 87 | hsa-miR-580-3p | 2 | 5p13.2 |
| 15 | 86 | hsa-miR-6792-3p | 4 | 19p13.2 |
| 16 | 86 | hsa-miR-3128 | 1 | 2q31.2 |
| 17 | 86 | hsa-miR-3934-5p | 3 | 6p21.31 |
| 18 | 86 | hsa-miR-4691-5p | 4 | 11q13.2 |
| 19 | 85 | hsa-miR-6733-3p | 2 | 1p34.2 |
| 20 | 85 | hsa-miR-4450 | 2 | 4q21.1 |
| 21 | 85 | hsa-miR-4267 | 3 | 2q13 |
| 22 | 85 | hsa-miR-205-3p | 4 | 1q32.2 |
| 23 | 84 | hsa-miR-4477b | 1 | 9p11.2 |
| 24 | 84 | hsa-miR-545-3p | 3 | Xq13.2 |
| 25 | 84 | hsa-miR-4465 | 3 | 6q24.1 |
| 26 | 84 | hsa-miR-371a-5p | 3 | 19q13.42 |
| 27 | 84 | hsa-miR-4775 | 5 | 2q33.3 |
| 28 | 83 | hsa-miR-4277 | 3 | 5p15.33 |
| 29 | 83 | hsa-miR-9985 | 2 | Yp11.2 |
| 30 | 83 | hsa-miR-3184-3p | 3 | 17q11.2 |
| 31 | 83 | hsa-miR-27a-3p | 2 | 19p13.12 |
| 32 | 83 | hsa-miR-27b-3p | 2 | 9q22.32 |
| 33 | 82 | hsa-miR-4729 | 2 | 17q22 |
| 34 | 82 | hsa-miR-138-1-3p | 2 | 3p21.32 |
| 35 | 81 | hsa-miR-4777-5p | 2 | 2q37.1 |
| 36 | 80 | hsa-miR-4670-3p | 1 | 9q22.31 |
Fig 3Binding of miRNAs in 3′ UTR of CPPED1.
Seed locations of miRNAs analyzed for binding to the 3′ UTR of CPPED1 by luciferase reporter assay (a). MiR-371a-5p has three seed locations, starting at 1602, 2033, and 4607 nucleotides. MiR-520d-5p and miR-524-5p share the same seed location in the end of 3′ UTR of CPPED1, which starts at nucleotide 5076. Seed locations are not to scale with respect to one another. For the luciferase assays, two variants of the 3′ UTR of CPPED1 were constructed. One construct contained the full-length 3′ UTR (WT). The other construct (Mut) lacked the 33 terminal nucleotides containing the miRNA binding sites for miR-520d-5p and miR-524-5p. Black dots roughly mark every thousand kilobases (kb). Bottom part of the figure shows luciferase reporter–based assays to detect binding of miR-371a-5p (b), miR-520d-5p (c), and miR-524-5p (d) mimics to the 3′ UTR of CPPED1 mRNA. WT or Mut constructs were cotransfected with miR371a-5p mimic (WT/miR-371a-5p) (b), miR-520d-5p mimic (WT/miR-520d-5p or Mut/miR-520d-5p) (c), or miR-524-5p mimic (WT/miR-524-5p or Mut/miR-524-5p) (d) into HEK-293T cells. For WT miR-neg and Mut miR-neg, the miRNA mimic negative control was cotransfected with WT or Mut constructs, respectively. Luciferase activities were measured by dual luciferase reporter assay, in which Firefly luciferase was the experimental reporter and Renilla luciferase the control reporter. Negative control values were set to 1.00 (WT/miR-neg), to which the rest of the samples were compared. Columns show the mean value of relative luciferase activity of six replicates; maximum and minimum values are also indicated. Statistically significant changes were determined by Mann–Whitney U test and are indicated by an asterisk (p < 0.05) or two asterisks (p < 0.01). NS, not significant.